Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$103.02 USD
+1.64 (1.62%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $103.04 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Axsome Therapeutics, Inc.'s return on equity, or ROE, is -272.80% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that AXSM has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
AXSM 103.02 +1.64(1.62%)
Will AXSM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXSM
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?
Other News for AXSM
Here are the major earnings before the open Monday
A Look at Axsome Therapeutics's Upcoming Earnings Report
Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy
Axsome Therapeutics Breaks Below 200-Day Moving Average - Notable for AXSM
Axsome Therapeutics (AXSM) to Highlight CNS Pipeline at R&D Day | AXSM Stock News